[Remote] Vice President of Sales, Prenatal at BillionToOne

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Medical Diagnostics, Prenatal and Cancer DiagnosticsIndustries

Skills

Key technologies and capabilities for this role

Sales StrategyTeam BuildingLeadershipMentoringPrenatal TestingProduct AdoptionRevenue Growth

Questions & Answers

Common questions about this position

What salary or compensation is offered for this VP of Sales role?

This information is not specified in the job description.

Is this VP of Sales position remote or does it require office work?

This information is not specified in the job description.

What are the key qualifications and skills required for this role?

Candidates need 15+ years of progressive sales leadership in the laboratory/diagnostics industry, experience managing 100+ sales reps in a multi-layer structure, a proven track record of exceeding targets, scaling high-growth sales organizations, and expertise in specialty molecular diagnostics, with women's health/prenatal preferred.

What is the company culture like at BillionToOne?

BillionToOne fosters a culture of transparency, collaboration, and innovation, focused on transforming healthcare through molecular diagnostics and making life-changing diagnostics accessible to all.

What makes a strong candidate for the VP of Prenatal Sales position?

A strong candidate has 15+ years in diagnostics sales leadership, experience scaling teams of 100+ reps, a history of exceeding targets in high-growth settings, and must-have expertise in specialty molecular diagnostics.

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.

Menlo Park, CaliforniaHeadquarters

2016Year Founded

$380.2MTotal Funding

SERIES_DCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Risks

Emerging biotech startups could threaten BillionToOne's market share.

Rapid technological advancements may render their current technology obsolete.

Expansion into new facilities may face operational challenges or delays.

Differentiation

BillionToOne's QCT technology detects DNA variations at single base-pair resolution.

Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.

They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.

Upsides

BillionToOne achieved a billion-dollar valuation with a $130 million funding round.

Their new Austin facility will create 1,000 jobs, boosting production and local economy.

Recognition as Diagnostics Company of the Year highlights their industry leadership.

Land your dream remote job 3x faster with AI

Try Jobo Free